Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review
International Forum of Allergy & Rhinology · 2026-11 · 16 (11) · 1342-1351
DOI: 10.1002/alr.70264 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 09.09.2026. Verfasst von Arun Chakravorty und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Endoscopy, Rhinosinusitis, Biological Therapy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS.
Methods
PubMed was searched through December 2025 for RCTs and subgroup analyses of biologics or ESS for adult CRSwNP. Included were ten Phase‐3 placebo‐controlled biologic RCTs, two pragmatic ESS trials, and one head‐to‐head biologic trial. 22‐Item Sino‐Nasal Outcome Test (SNOT‐22) and nasal polyp score (NPS) effect sizes and subgroup interactions were extracted.
Results
A total of 13 trials ( n = 3775) from 21 publications were included. By indirect comparison, tezepelumab and dupilumab produced the largest improvements (tezepelumab: SNOT‐22: −27.4; NPS: −2.1; dupilumab: SNOT‐22: −17 to −21; NPS: −1.7 to −2.1), while mepolizumab and omalizumab showed intermediate effects (SNOT‐22: −10.6 to −16.5); benralizumab improved NPS but not SNOT‐22, and depemokimab showed improvement below clinically discernible differences. ESS effects varied by trial and follow‐up (SNOT‐22: −21.9 at 6 months in MACRO vs. −4.9 at 12 months in PolypESS). Predictors of improvement differed across therapies (blood eosinophil count, NSAID‐exacerbated respiratory disease, and prior ESS for dupilumab; asthma for benralizumab; baseline severity for ESS), while tezepelumab and omalizumab showed consistent efficacy without effect modification.
Conclusions
ESS and biologics provide clinically meaningful benefit. Among biologics, dupilumab and tezepelumab demonstrated the largest effect sizes, though cross‐trial differences in baseline severity, follow‐up, and comparators limit indirect comparisons. Head‐to‐head trials and standardized subgroup analyses are needed to guide treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- UCLA-Caltech Medical Scientist Training Program, Los Angeles, California, USA.
- Department of Otolaryngology - Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Otolaryngology - Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: Arun Chakravorty, Jess C Mace, Timothy L Smith, Daniel M Beswick
Zitieren
APA
Chakravorty, A., Lin, M. E., Lubner, R., Mace, J. C., Suh, J., Lee, J., Wang, M., Wise, S., Chowdhury, N., Soler, Z. M., Turner, J., Smith, T. L., Sim, M., & Beswick, D. M. (2026). Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review. International Forum of Allergy & Rhinology, 16(11), 1342-1351. https://doi.org/10.1002/alr.70264
Vancouver
Chakravorty A, Lin ME, Lubner R, Mace JC, Suh J, Lee J, et al. Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review. International Forum of Allergy & Rhinology. 2026;16(11):1342-1351. doi:10.1002/alr.70264
BibTeX
@article{Chakravorty2026,
author = {Chakravorty, Arun and Lin, Matthew E and Lubner, Rory and Mace, Jess C and Suh, Jeffrey and Lee, Jivianne and Wang, Marilene and Wise, Sarah and Chowdhury, Naweed and Soler, Zachary M and Turner, Justin and Smith, Timothy L and Sim, Myung and Beswick, Daniel M},
title = {Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
volume = {16},
number = {11},
pages = {1342--1351},
doi = {10.1002/alr.70264}
}
EUVIMED